Généthon receives the 2012 Galien Prize for its Innovative Treatments in Gene Therapy
The 43rd Prix Galien recognized Généthon for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of "Medicines destined for rare diseases - cell therapy and gene therapy." Created in 1990 by a patient association, the AFM-Téléthon, and 90% financed by donations from the French Téléthon, Généthon is dedicated to the development of gene therapy treatments for rare diseases - from their discovery through production and through their pre-clinical and clinical development. This is the first time that a non-profit organization, created by a patient association, has received the Galien Prize.
Frédéric Revah, Chief Executive Officer of Généthon, said "This prestigious prize, awarded to a laboratory created by a patient association and funded by public generosity, confirms the incontestable role of Généthon as world leader in the field of gene therapy, and recognizes its major contribution to medicine in general and to the treatment of rare diseases specifically."
Other news from the department business & finance
